Company Analysis

LB Pharmaceuticals Inc (LBRX)

Nasdaq: LBRX · Pharmaceutical Preparations · New York, NY · filing with the SEC since 2016
Grade5.6
◀ Past 4.1● Present 6.1▶ Future 6.1
7 est.

Who owns LB Pharmaceuticals Inc

As filed with the SEC
Holders of 5% or more
8
Deep Track Capital, LP holds 11.7% of Common Stock, $0.0001 par value per share, as its SCHEDULE 13D/A filed Feb 10, 2026 says.
Directors and officers
16
report now, of 16 people on the record since 2025. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 8 named at left.
Holders of 5% or moreshare of the class, as filed
Deep Track Capital, LP
SCHEDULE 13D/A · filed Feb 10, 2026 · Common Stock, $0.0001 par value per share · 14.9% in Sep 19, 2025
11.7%
RA Capital Management, L.P.
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, $0.0001 par value per share · 7.5% in Sep 19, 2025
8.7%
Commodore Capital LP
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, $0.0001 par value per share · 5.5% in Sep 18, 2025
6.8%
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 29, 2026 · Common Stock · 5.1% in Jan 21, 2026
6.3%
Pontifax Management 4 G.P. (2015) Ltd.
SCHEDULE 13D · filed Sep 25, 2025 · Common Stock, $0.0001 par value per share
6.3%
TCG Crossover GP II, LLC
SCHEDULE 13G/A · filed Aug 14, 2026 · Common Stock, par value $0.0001 per share · 6.4% in May 15, 2026
5%
Caligan Partners LP
SCHEDULE 13G · filed May 15, 2026 · Common Stock, $0.0001 par value per share
5%
Trails Edge Capital Partners, LP
SCHEDULE 13G · filed Dec 31, 2025 · Common Stock, par value $0.0001
5%
JPMorgan Chase & Co.
SCHEDULE 13G/A · filed Oct 13, 2026 · Common Stock, $0.0001 par value · reported falling below 5%, from 5.2% in Jul 16, 2026
under 5%
BlackRock Portfolio Management LLC
SCHEDULE 13G/A · filed Jan 21, 2026 · Common Stock · reported falling below 5%, from 5.9% in Oct 17, 2025
under 5%
What LBRX reports owning in othersstakes of 5% or more, and other ties
LB Pharmaceuticals Inc reports no stake in another company in the record.
Insider tradesForm 4
0sales
0purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 13, 2025 to Oct 13, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
25
2025 runs to Oct 13, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window
No one on the roster filed an open-market trade in the window.
SI Assistanton LBRX · research, not advice